Literature DB >> 32357977

Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic.

Elizabeth Price1, Elizabeth MacPhie2, Lesley Kay3, Peter Lanyon4, Bridget Griffiths5, Christopher Holroyd6, Abhishek Abhishek7, Taryn Youngstein8, Kathryn Bailey9, Jacqui Clinch10, Muddassir Shaikh11, Ali Rivett12.   

Abstract

Rheumatology teams care for patients with diverse, systemic autoimmune diseases who are often immunosuppressed and at high risk of infections. The current COVID-19 pandemic has presented particular challenges in caring for and managing this patient group. The office of the chief medical officer (CMO) for England contacted the rheumatology community to provide expert advice on the identification of extremely vulnerable patients at very high risk during the COVID-19 pandemic who should be 'shielded'. This involves the patients being asked to strictly self-isolate for at least 12 weeks with additional funded support provided for them to remain at home. A group of rheumatologists (the authors) have devised a pragmatic guide to identifying the very highest risk group using a rapidly developed scoring system which went live simultaneous with the Government announcement on shielding and was cascaded to all rheumatologists working in England. © Royal College of Physicians 2020. All rights reserved.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; health economics; innovation; testing

Year:  2020        PMID: 32357977     DOI: 10.7861/clinmed.2020-0160

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  6 in total

1.  COVID-19: the physician's response in the first phase.

Authors:  Anton Emmanuel
Journal:  Clin Med (Lond)       Date:  2020-05       Impact factor: 2.659

2.  Perceptions of risk in people with inflammatory arthritis during the COVID-19 pandemic.

Authors:  Sarah Ryan; Paul Campbell; Zoe Paskins; Fay Manning; Katrina Rule; Michael Brooks; Samantha Hider; Andrew Hassell
Journal:  Rheumatol Adv Pract       Date:  2022-06-20

Review 3.  Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes.

Authors:  Efstathios Kastritis; George D Kitas; Dimitrios Vassilopoulos; Georgios Giannopoulos; Meletios A Dimopoulos; Petros P Sfikakis
Journal:  Rheumatol Int       Date:  2020-07-11       Impact factor: 2.631

4.  Health-related quality of life, uncertainty and coping strategies in solid organ transplant recipients during shielding for the COVID-19 pandemic.

Authors:  Siobhan C McKay; Hanns Lembach; Angus Hann; Kelvin Okoth; Joy Anderton; Krishnarajah Nirantharakumar; Laura Magill; Barbara Torlinska; Matthew Armstrong; Jorge Mascaro; Nicholas Inston; Thomas Pinkney; Aaron Ranasinghe; Richard Borrows; James Ferguson; John Isaac; Melanie Calvert; M Thamara P R Perera; Hermien Hartog
Journal:  Transpl Int       Date:  2021-09-16       Impact factor: 3.842

5.  Patients' perspectives of telemedicine appointments for psoriatic arthritis during the COVID-19 pandemic: results of a patient-driven pilot survey.

Authors:  Hannah Jethwa; Melanie Brooke; Andrew Parkinson; Emma Dures; Nicola J Gullick
Journal:  BMC Rheumatol       Date:  2022-02-22

6.  Attitudes of patients with spondylarthritis or rheumatoid arthritis regarding biological treatment during COVID-19 pandemic: A multi-center, phone-based, cross-sectional study.

Authors:  Coskun Zateri; Murat Birtane; İlknur Aktaş; Selda Sarıkaya; Aylin Rezvani; Lale Altan; Nigar Dursun; Erbil Dursun; Nurettin Taştekin; Reyhan Çeliker; Şenay Özdolap; Kenan Akgün
Journal:  Arch Rheumatol       Date:  2021-06-24       Impact factor: 1.472

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.